nodes	percent_of_prediction	percent_of_DWPC	metapath
Dolutegravir—Musculoskeletal disorder—Salbutamol—chronic obstructive pulmonary disease	0.0316	0.038	CcSEcCtD
Dolutegravir—UGT1A1—Heme degradation—HMOX1—chronic obstructive pulmonary disease	0.0168	0.104	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—IL13—chronic obstructive pulmonary disease	0.0128	0.0792	CbGpPWpGaD
Dolutegravir—Hepatobiliary disease—Roflumilast—chronic obstructive pulmonary disease	0.0125	0.015	CcSEcCtD
Dolutegravir—Inflammation—Formoterol—chronic obstructive pulmonary disease	0.0123	0.0148	CcSEcCtD
Dolutegravir—Inflammation—Arformoterol—chronic obstructive pulmonary disease	0.0123	0.0148	CcSEcCtD
Dolutegravir—Opportunistic infection—Prednisone—chronic obstructive pulmonary disease	0.0117	0.014	CcSEcCtD
Dolutegravir—Inflammation—Salbutamol—chronic obstructive pulmonary disease	0.0116	0.014	CcSEcCtD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—SLC6A4—chronic obstructive pulmonary disease	0.0115	0.0715	CbGpPWpGaD
Dolutegravir—Immune system disorder—Roflumilast—chronic obstructive pulmonary disease	0.0107	0.0128	CcSEcCtD
Dolutegravir—Abdominal pain upper—Aminophylline—chronic obstructive pulmonary disease	0.0104	0.0125	CcSEcCtD
Dolutegravir—Mental disorder—Roflumilast—chronic obstructive pulmonary disease	0.0104	0.0125	CcSEcCtD
Dolutegravir—Vertigo—Roflumilast—chronic obstructive pulmonary disease	0.00925	0.0111	CcSEcCtD
Dolutegravir—Hyperglycaemia—Aminophylline—chronic obstructive pulmonary disease	0.00889	0.0107	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Roflumilast—chronic obstructive pulmonary disease	0.00871	0.0105	CcSEcCtD
Dolutegravir—UGT1A1—Estrogen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.00848	0.0526	CbGpPWpGaD
Dolutegravir—Hyperglycaemia—Tiotropium—chronic obstructive pulmonary disease	0.00839	0.0101	CcSEcCtD
Dolutegravir—Nervous system disorder—Roflumilast—chronic obstructive pulmonary disease	0.00824	0.0099	CcSEcCtD
Dolutegravir—Skin disorder—Roflumilast—chronic obstructive pulmonary disease	0.00817	0.00981	CcSEcCtD
Dolutegravir—Renal failure—Tiotropium—chronic obstructive pulmonary disease	0.00815	0.00979	CcSEcCtD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—IL10—chronic obstructive pulmonary disease	0.00799	0.0496	CbGpPWpGaD
Dolutegravir—Insomnia—Roflumilast—chronic obstructive pulmonary disease	0.0076	0.00914	CcSEcCtD
Dolutegravir—Alanine aminotransferase increased—Montelukast—chronic obstructive pulmonary disease	0.0075	0.00901	CcSEcCtD
Dolutegravir—Abdominal pain upper—Salbutamol—chronic obstructive pulmonary disease	0.00749	0.00899	CcSEcCtD
Dolutegravir—Urinary tract disorder—Tiotropium—chronic obstructive pulmonary disease	0.00735	0.00883	CcSEcCtD
Dolutegravir—UGT1A1—Porphyrin metabolism—HMOX1—chronic obstructive pulmonary disease	0.0073	0.0453	CbGpPWpGaD
Dolutegravir—Urethral disorder—Tiotropium—chronic obstructive pulmonary disease	0.00729	0.00876	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Roflumilast—chronic obstructive pulmonary disease	0.00726	0.00872	CcSEcCtD
Dolutegravir—Fatigue—Roflumilast—chronic obstructive pulmonary disease	0.00725	0.00871	CcSEcCtD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—HTR2A—chronic obstructive pulmonary disease	0.00707	0.0439	CbGpPWpGaD
Dolutegravir—Gastrointestinal pain—Roflumilast—chronic obstructive pulmonary disease	0.00687	0.00826	CcSEcCtD
Dolutegravir—Hyperglycaemia—Formoterol—chronic obstructive pulmonary disease	0.00677	0.00813	CcSEcCtD
Dolutegravir—Hyperglycaemia—Arformoterol—chronic obstructive pulmonary disease	0.00677	0.00813	CcSEcCtD
Dolutegravir—Immune system disorder—Tiotropium—chronic obstructive pulmonary disease	0.00672	0.00808	CcSEcCtD
Dolutegravir—Abdominal pain—Roflumilast—chronic obstructive pulmonary disease	0.00665	0.00798	CcSEcCtD
Dolutegravir—Mental disorder—Tiotropium—chronic obstructive pulmonary disease	0.00652	0.00783	CcSEcCtD
Dolutegravir—UGT1A1—Estrogen metabolism—GSTM1—chronic obstructive pulmonary disease	0.0065	0.0403	CbGpPWpGaD
Dolutegravir—Hyperglycaemia—Salbutamol—chronic obstructive pulmonary disease	0.00639	0.00768	CcSEcCtD
Dolutegravir—Hepatobiliary disease—Montelukast—chronic obstructive pulmonary disease	0.0062	0.00745	CcSEcCtD
Dolutegravir—Hypersensitivity—Roflumilast—chronic obstructive pulmonary disease	0.00619	0.00744	CcSEcCtD
Dolutegravir—UGT1A1—Estrogen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.00616	0.0382	CbGpPWpGaD
Dolutegravir—Asthenia—Roflumilast—chronic obstructive pulmonary disease	0.00603	0.00725	CcSEcCtD
Dolutegravir—Urinary tract disorder—Formoterol—chronic obstructive pulmonary disease	0.00593	0.00713	CcSEcCtD
Dolutegravir—Urinary tract disorder—Arformoterol—chronic obstructive pulmonary disease	0.00593	0.00713	CcSEcCtD
Dolutegravir—Urethral disorder—Formoterol—chronic obstructive pulmonary disease	0.00589	0.00707	CcSEcCtD
Dolutegravir—Urethral disorder—Arformoterol—chronic obstructive pulmonary disease	0.00589	0.00707	CcSEcCtD
Dolutegravir—Hepatitis—Montelukast—chronic obstructive pulmonary disease	0.00588	0.00707	CcSEcCtD
Dolutegravir—Urinary tract disorder—Montelukast—chronic obstructive pulmonary disease	0.00581	0.00698	CcSEcCtD
Dolutegravir—Urethral disorder—Montelukast—chronic obstructive pulmonary disease	0.00577	0.00693	CcSEcCtD
Dolutegravir—Diarrhoea—Roflumilast—chronic obstructive pulmonary disease	0.00575	0.00691	CcSEcCtD
Dolutegravir—Urinary tract disorder—Salbutamol—chronic obstructive pulmonary disease	0.0056	0.00673	CcSEcCtD
Dolutegravir—Dizziness—Roflumilast—chronic obstructive pulmonary disease	0.00556	0.00668	CcSEcCtD
Dolutegravir—Urethral disorder—Salbutamol—chronic obstructive pulmonary disease	0.00556	0.00668	CcSEcCtD
Dolutegravir—Nervous system disorder—Aminophylline—chronic obstructive pulmonary disease	0.0055	0.00661	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Tiotropium—chronic obstructive pulmonary disease	0.00548	0.00658	CcSEcCtD
Dolutegravir—Immune system disorder—Formoterol—chronic obstructive pulmonary disease	0.00542	0.00652	CcSEcCtD
Dolutegravir—Immune system disorder—Arformoterol—chronic obstructive pulmonary disease	0.00542	0.00652	CcSEcCtD
Dolutegravir—Vomiting—Roflumilast—chronic obstructive pulmonary disease	0.00534	0.00642	CcSEcCtD
Dolutegravir—Immune system disorder—Montelukast—chronic obstructive pulmonary disease	0.00531	0.00638	CcSEcCtD
Dolutegravir—Rash—Roflumilast—chronic obstructive pulmonary disease	0.0053	0.00637	CcSEcCtD
Dolutegravir—Dermatitis—Roflumilast—chronic obstructive pulmonary disease	0.0053	0.00636	CcSEcCtD
Dolutegravir—Headache—Roflumilast—chronic obstructive pulmonary disease	0.00527	0.00633	CcSEcCtD
Dolutegravir—Mental disorder—Formoterol—chronic obstructive pulmonary disease	0.00526	0.00632	CcSEcCtD
Dolutegravir—Mental disorder—Arformoterol—chronic obstructive pulmonary disease	0.00526	0.00632	CcSEcCtD
Dolutegravir—Nervous system disorder—Tiotropium—chronic obstructive pulmonary disease	0.00518	0.00623	CcSEcCtD
Dolutegravir—Mental disorder—Montelukast—chronic obstructive pulmonary disease	0.00515	0.00619	CcSEcCtD
Dolutegravir—Skin disorder—Tiotropium—chronic obstructive pulmonary disease	0.00513	0.00617	CcSEcCtD
Dolutegravir—Immune system disorder—Salbutamol—chronic obstructive pulmonary disease	0.00512	0.00615	CcSEcCtD
Dolutegravir—Insomnia—Aminophylline—chronic obstructive pulmonary disease	0.00507	0.00609	CcSEcCtD
Dolutegravir—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.00499	0.006	CcSEcCtD
Dolutegravir—Mental disorder—Salbutamol—chronic obstructive pulmonary disease	0.00497	0.00597	CcSEcCtD
Dolutegravir—Flatulence—Salbutamol—chronic obstructive pulmonary disease	0.00486	0.00584	CcSEcCtD
Dolutegravir—Insomnia—Tiotropium—chronic obstructive pulmonary disease	0.00478	0.00574	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.00458	0.00551	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.00456	0.00548	CcSEcCtD
Dolutegravir—Vertigo—Salbutamol—chronic obstructive pulmonary disease	0.00443	0.00533	CcSEcCtD
Dolutegravir—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.00443	0.00532	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.00442	0.00531	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.00442	0.00531	CcSEcCtD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—CXCL8—chronic obstructive pulmonary disease	0.00437	0.0271	CbGpPWpGaD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.00433	0.0052	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.00432	0.00519	CcSEcCtD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—IL1B—chronic obstructive pulmonary disease	0.00419	0.026	CbGpPWpGaD
Dolutegravir—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.00418	0.00503	CcSEcCtD
Dolutegravir—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.00418	0.00503	CcSEcCtD
Dolutegravir—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.00418	0.00502	CcSEcCtD
Dolutegravir—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.00414	0.00498	CcSEcCtD
Dolutegravir—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.00414	0.00498	CcSEcCtD
Dolutegravir—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.00413	0.00496	CcSEcCtD
Dolutegravir—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.0041	0.00492	CcSEcCtD
Dolutegravir—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.00406	0.00488	CcSEcCtD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—CYP1A2—chronic obstructive pulmonary disease	0.004	0.0248	CbGpPWpGaD
Dolutegravir—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.00397	0.00477	CcSEcCtD
Dolutegravir—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.00395	0.00475	CcSEcCtD
Dolutegravir—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.00391	0.0047	CcSEcCtD
Dolutegravir—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.00389	0.00468	CcSEcCtD
Dolutegravir—POU2F2—bronchus—chronic obstructive pulmonary disease	0.00389	0.608	CbGeAlD
Dolutegravir—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.00386	0.00464	CcSEcCtD
Dolutegravir—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.00386	0.00464	CcSEcCtD
Dolutegravir—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.00384	0.00461	CcSEcCtD
Dolutegravir—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.00378	0.00454	CcSEcCtD
Dolutegravir—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.00374	0.00449	CcSEcCtD
Dolutegravir—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.00371	0.00445	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.00368	0.00443	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.00368	0.00443	CcSEcCtD
Dolutegravir—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.00368	0.00442	CcSEcCtD
Dolutegravir—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.00368	0.00442	CcSEcCtD
Dolutegravir—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.00364	0.00438	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.00361	0.00433	CcSEcCtD
Dolutegravir—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.0036	0.00433	CcSEcCtD
Dolutegravir—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.00356	0.00428	CcSEcCtD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—VEGFA—chronic obstructive pulmonary disease	0.00355	0.022	CbGpPWpGaD
Dolutegravir—Rash—Aminophylline—chronic obstructive pulmonary disease	0.00353	0.00425	CcSEcCtD
Dolutegravir—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.00353	0.00424	CcSEcCtD
Dolutegravir—Headache—Aminophylline—chronic obstructive pulmonary disease	0.00351	0.00422	CcSEcCtD
Dolutegravir—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.0035	0.0042	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.00349	0.00419	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.00349	0.00419	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.00348	0.00418	CcSEcCtD
Dolutegravir—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.00347	0.00417	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.00342	0.00411	CcSEcCtD
Dolutegravir—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.00337	0.00405	CcSEcCtD
Dolutegravir—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.00337	0.00405	CcSEcCtD
Dolutegravir—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.00336	0.00404	CcSEcCtD
Dolutegravir—Rash—Tiotropium—chronic obstructive pulmonary disease	0.00333	0.004	CcSEcCtD
Dolutegravir—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.00333	0.004	CcSEcCtD
Dolutegravir—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.00333	0.004	CcSEcCtD
Dolutegravir—Headache—Tiotropium—chronic obstructive pulmonary disease	0.00331	0.00398	CcSEcCtD
Dolutegravir—UGT1A1—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.00331	0.0205	CbGpPWpGaD
Dolutegravir—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.0033	0.00397	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.00329	0.00396	CcSEcCtD
Dolutegravir—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.00318	0.00383	CcSEcCtD
Dolutegravir—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.00314	0.00378	CcSEcCtD
Dolutegravir—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.00314	0.00378	CcSEcCtD
Dolutegravir—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.00314	0.00377	CcSEcCtD
Dolutegravir—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.00308	0.0037	CcSEcCtD
Dolutegravir—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.00306	0.00368	CcSEcCtD
Dolutegravir—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.00306	0.00368	CcSEcCtD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—TNF—chronic obstructive pulmonary disease	0.00304	0.0189	CbGpPWpGaD
Dolutegravir—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.00302	0.00363	CcSEcCtD
Dolutegravir—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.00302	0.00363	CcSEcCtD
Dolutegravir—Alanine aminotransferase increased—Prednisone—chronic obstructive pulmonary disease	0.00301	0.00362	CcSEcCtD
Dolutegravir—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.003	0.0036	CcSEcCtD
Dolutegravir—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.00297	0.00357	CcSEcCtD
Dolutegravir—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.00296	0.00355	CcSEcCtD
Dolutegravir—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.00292	0.00351	CcSEcCtD
Dolutegravir—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.00292	0.00351	CcSEcCtD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—CYP1A1—chronic obstructive pulmonary disease	0.00291	0.018	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—SOD3—chronic obstructive pulmonary disease	0.0029	0.018	CbGpPWpGaD
Dolutegravir—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.00289	0.00347	CcSEcCtD
Dolutegravir—UGT1A1—Phase II conjugation—GSTT1—chronic obstructive pulmonary disease	0.00287	0.0178	CbGpPWpGaD
Dolutegravir—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.00286	0.00344	CcSEcCtD
Dolutegravir—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.00285	0.00342	CcSEcCtD
Dolutegravir—UGT1A1—Phase II conjugation—GCLC—chronic obstructive pulmonary disease	0.00283	0.0176	CbGpPWpGaD
Dolutegravir—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.00282	0.00339	CcSEcCtD
Dolutegravir—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.00282	0.00339	CcSEcCtD
Dolutegravir—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.00276	0.00332	CcSEcCtD
Dolutegravir—Neutropenia—Prednisone—chronic obstructive pulmonary disease	0.00276	0.00332	CcSEcCtD
Dolutegravir—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.00276	0.00331	CcSEcCtD
Dolutegravir—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.00271	0.00326	CcSEcCtD
Dolutegravir—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.00271	0.00326	CcSEcCtD
Dolutegravir—Rash—Arformoterol—chronic obstructive pulmonary disease	0.00269	0.00323	CcSEcCtD
Dolutegravir—Rash—Formoterol—chronic obstructive pulmonary disease	0.00269	0.00323	CcSEcCtD
Dolutegravir—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.00269	0.00323	CcSEcCtD
Dolutegravir—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.00269	0.00323	CcSEcCtD
Dolutegravir—Headache—Arformoterol—chronic obstructive pulmonary disease	0.00267	0.00321	CcSEcCtD
Dolutegravir—Headache—Formoterol—chronic obstructive pulmonary disease	0.00267	0.00321	CcSEcCtD
Dolutegravir—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.00266	0.0032	CcSEcCtD
Dolutegravir—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	0.00266	0.0032	CcSEcCtD
Dolutegravir—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.00266	0.00319	CcSEcCtD
Dolutegravir—Rash—Montelukast—chronic obstructive pulmonary disease	0.00263	0.00317	CcSEcCtD
Dolutegravir—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.00263	0.00316	CcSEcCtD
Dolutegravir—Headache—Montelukast—chronic obstructive pulmonary disease	0.00262	0.00315	CcSEcCtD
Dolutegravir—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.00256	0.00308	CcSEcCtD
Dolutegravir—Vertigo—Prednisolone—chronic obstructive pulmonary disease	0.00254	0.00306	CcSEcCtD
Dolutegravir—Rash—Salbutamol—chronic obstructive pulmonary disease	0.00254	0.00305	CcSEcCtD
Dolutegravir—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.00254	0.00305	CcSEcCtD
Dolutegravir—Nausea—Formoterol—chronic obstructive pulmonary disease	0.00253	0.00304	CcSEcCtD
Dolutegravir—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.00253	0.00304	CcSEcCtD
Dolutegravir—Headache—Salbutamol—chronic obstructive pulmonary disease	0.00252	0.00303	CcSEcCtD
Dolutegravir—POU2F2—lung—chronic obstructive pulmonary disease	0.00251	0.392	CbGeAlD
Dolutegravir—Nausea—Montelukast—chronic obstructive pulmonary disease	0.00248	0.00298	CcSEcCtD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—IL6—chronic obstructive pulmonary disease	0.00246	0.0152	CbGpPWpGaD
Dolutegravir—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.00239	0.00288	CcSEcCtD
Dolutegravir—UGT1A1—Phase II conjugation—CYP1A2—chronic obstructive pulmonary disease	0.00238	0.0148	CbGpPWpGaD
Dolutegravir—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	0.00213	0.00256	CcSEcCtD
Dolutegravir—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.00209	0.00251	CcSEcCtD
Dolutegravir—Mental disorder—Prednisone—chronic obstructive pulmonary disease	0.00207	0.00249	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—SERPINA1—chronic obstructive pulmonary disease	0.00207	0.0128	CbGpPWpGaD
Dolutegravir—UGT1A1—Phase II conjugation—GSTP1—chronic obstructive pulmonary disease	0.00199	0.0123	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—GCLC—chronic obstructive pulmonary disease	0.00189	0.0117	CbGpPWpGaD
Dolutegravir—Vertigo—Prednisone—chronic obstructive pulmonary disease	0.00185	0.00222	CcSEcCtD
Dolutegravir—UGT1A1—Phase II conjugation—GSTM1—chronic obstructive pulmonary disease	0.00183	0.0113	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—TGFB2—chronic obstructive pulmonary disease	0.00179	0.0111	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—SLC6A4—chronic obstructive pulmonary disease	0.00176	0.0109	CbGpPWpGaD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.00174	0.00209	CcSEcCtD
Dolutegravir—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.0017	0.00205	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.00168	0.0104	CbGpPWpGaD
Dolutegravir—UGT1A1—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.00166	0.0103	CbGpPWpGaD
Dolutegravir—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	0.00165	0.00198	CcSEcCtD
Dolutegravir—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.00163	0.00196	CcSEcCtD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL1B—chronic obstructive pulmonary disease	0.00161	0.00998	CbGpPWpGaD
Dolutegravir—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.00153	0.00184	CcSEcCtD
Dolutegravir—Insomnia—Prednisone—chronic obstructive pulmonary disease	0.00152	0.00182	CcSEcCtD
Dolutegravir—Rash—Prednisolone—chronic obstructive pulmonary disease	0.00146	0.00175	CcSEcCtD
Dolutegravir—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.00146	0.00175	CcSEcCtD
Dolutegravir—Fatigue—Prednisone—chronic obstructive pulmonary disease	0.00145	0.00174	CcSEcCtD
Dolutegravir—Headache—Prednisolone—chronic obstructive pulmonary disease	0.00145	0.00174	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	0.00139	0.00864	CbGpPWpGaD
Dolutegravir—UGT1A1—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	0.00137	0.00852	CbGpPWpGaD
Dolutegravir—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	0.00137	0.00165	CcSEcCtD
Dolutegravir—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.00137	0.00165	CcSEcCtD
Dolutegravir—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	0.00133	0.00159	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—GSTP1—chronic obstructive pulmonary disease	0.00133	0.00822	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—HMOX1—chronic obstructive pulmonary disease	0.00131	0.0081	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TGFB1—chronic obstructive pulmonary disease	0.00125	0.00775	CbGpPWpGaD
Dolutegravir—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	0.00124	0.00149	CcSEcCtD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—chronic obstructive pulmonary disease	0.00123	0.0076	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—GSTM1—chronic obstructive pulmonary disease	0.00122	0.00755	CbGpPWpGaD
Dolutegravir—Asthenia—Prednisone—chronic obstructive pulmonary disease	0.0012	0.00145	CcSEcCtD
Dolutegravir—Pruritus—Prednisone—chronic obstructive pulmonary disease	0.00119	0.00143	CcSEcCtD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TNF—chronic obstructive pulmonary disease	0.00117	0.00724	CbGpPWpGaD
Dolutegravir—UGT1A1—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	0.00116	0.00721	CbGpPWpGaD
Dolutegravir—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	0.00115	0.00138	CcSEcCtD
Dolutegravir—UGT1A1—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	0.00115	0.00711	CbGpPWpGaD
Dolutegravir—Dizziness—Prednisone—chronic obstructive pulmonary disease	0.00111	0.00133	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	0.00107	0.00662	CbGpPWpGaD
Dolutegravir—Vomiting—Prednisone—chronic obstructive pulmonary disease	0.00107	0.00128	CcSEcCtD
Dolutegravir—Rash—Prednisone—chronic obstructive pulmonary disease	0.00106	0.00127	CcSEcCtD
Dolutegravir—Dermatitis—Prednisone—chronic obstructive pulmonary disease	0.00106	0.00127	CcSEcCtD
Dolutegravir—UGT1A1—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	0.00105	0.00653	CbGpPWpGaD
Dolutegravir—Headache—Prednisone—chronic obstructive pulmonary disease	0.00105	0.00126	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	0.00101	0.00628	CbGpPWpGaD
Dolutegravir—UGT1A1—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	0.000999	0.00619	CbGpPWpGaD
Dolutegravir—Nausea—Prednisone—chronic obstructive pulmonary disease	0.000997	0.0012	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—APIP—chronic obstructive pulmonary disease	0.000815	0.00505	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	0.00054	0.00335	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GC—chronic obstructive pulmonary disease	0.000525	0.00325	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—TGFB1—chronic obstructive pulmonary disease	0.000496	0.00308	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	0.000488	0.00303	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GSTT1—chronic obstructive pulmonary disease	0.000287	0.00178	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GCLC—chronic obstructive pulmonary disease	0.000283	0.00176	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CTGF—chronic obstructive pulmonary disease	0.000259	0.0016	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000238	0.00148	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GSTP1—chronic obstructive pulmonary disease	0.000199	0.00123	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—HMOX1—chronic obstructive pulmonary disease	0.000196	0.00122	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GSTM1—chronic obstructive pulmonary disease	0.000183	0.00113	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000173	0.00107	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ALB—chronic obstructive pulmonary disease	0.000118	0.00073	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—NOS3—chronic obstructive pulmonary disease	0.000113	0.000698	CbGpPWpGaD
